TF and cancer: We demonstrated the potential of HemaCisDB in identifying TF candidates that drive cancer pathogenesis by comparing TF footprints using ATAC-seq data of fluorescence-activated cell sorting (FACS)-purified myeloma cells from MM patients and normal B cells from primary human blood cells.